179 related articles for article (PubMed ID: 20029937)
1. Potential surrogate endpoints in cancer research--some considerations and examples.
Duffy SW; Treasure FP
Pharm Stat; 2011; 10(1):34-9. PubMed ID: 20029937
[TBL] [Abstract][Full Text] [Related]
2. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints.
Lassere MN
Stat Methods Med Res; 2008 Jun; 17(3):303-40. PubMed ID: 17925313
[TBL] [Abstract][Full Text] [Related]
3. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.
Lassere MN; Johnson KR; Boers M; Tugwell P; Brooks P; Simon L; Strand V; Conaghan PG; Ostergaard M; Maksymowych WP; Landewe R; Bresnihan B; Tak PP; Wakefield R; Mease P; Bingham CO; Hughes M; Altman D; Buyse M; Galbraith S; Wells G
J Rheumatol; 2007 Mar; 34(3):607-15. PubMed ID: 17343307
[TBL] [Abstract][Full Text] [Related]
4. Intermediate markers as surrogate endpoints in cancer research.
Schatzkin A
Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
[TBL] [Abstract][Full Text] [Related]
5. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
Powers JH
Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
[TBL] [Abstract][Full Text] [Related]
6. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
Sertdemir Y; Burgut R
Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
[TBL] [Abstract][Full Text] [Related]
7. [Surrogate and true endpoints in cancer clinical trials].
Nakajima T; Ohta K; Ohyama S; Yamaguchi T
Gan To Kagaku Ryoho; 2000 May; 27(5):671-5. PubMed ID: 10832433
[TBL] [Abstract][Full Text] [Related]
8. Assessing surrogates as trial endpoints using mixed models.
Korn EL; Albert PS; McShane LM
Stat Med; 2005 Jan; 24(2):163-82. PubMed ID: 15515150
[TBL] [Abstract][Full Text] [Related]
9. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
Lonn E
Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
[TBL] [Abstract][Full Text] [Related]
10. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
Buyse M
Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
[TBL] [Abstract][Full Text] [Related]
11. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
Renfro LA; Shi Q; Sargent DJ; Carlin BP
Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development.
Colburn WA
J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1419-27. PubMed ID: 11185662
[TBL] [Abstract][Full Text] [Related]
14. Does the Prentice criterion validate surrogate endpoints?
Berger VW
Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
[TBL] [Abstract][Full Text] [Related]
15. Statistical evaluation of biomarkers as surrogate endpoints: a literature review.
Weir CJ; Walley RJ
Stat Med; 2006 Jan; 25(2):183-203. PubMed ID: 16252272
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers as surrogate endpoints in cancer trials.
Dunn BK; Akpa E
Semin Oncol Nurs; 2012 May; 28(2):99-108. PubMed ID: 22542317
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology.
Carroll KJ
Pharm Stat; 2007; 6(4):253-60. PubMed ID: 17351904
[TBL] [Abstract][Full Text] [Related]
18. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach.
Alonso A; Geys H; Molenberghs G; Kenward MG; Vangeneugden T
Biometrics; 2004 Dec; 60(4):845-53. PubMed ID: 15606404
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements.
Broich K; Weiergräber M; Hampel H
Prog Neurobiol; 2011 Dec; 95(4):498-500. PubMed ID: 21945642
[TBL] [Abstract][Full Text] [Related]
20. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
